<SUBMISSION>
<ACCESSION-NUMBER>0000950123-10-092538
<TYPE>425
<PUBLIC-DOCUMENT-COUNT>2
<FILING-DATE>20101012
<DATE-OF-FILING-DATE-CHANGE>20101012
<SUBJECT-COMPANY>
<COMPANY-DATA>
<CONFORMED-NAME>Abraxis BioScience, Inc.
<CIK>0001409012
<ASSIGNED-SIC>2834
<IRS-NUMBER>300431735
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>425
<ACT>34
<FILE-NUMBER>001-33657
<FILM-NUMBER>101117389
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>11755 WILSHIRE BLVD., 20TH FLOOR
<CITY>LOS ANGELES
<STATE>CA
<ZIP>90025
<PHONE>310-883-1300
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>11755 WILSHIRE BLVD., 20TH FLOOR
<CITY>LOS ANGELES
<STATE>CA
<ZIP>90025
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>Abraxis Biosciences, Inc.
<DATE-CHANGED>20071120
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>New Abraxis, Inc.
<DATE-CHANGED>20070806
</FORMER-COMPANY>
</SUBJECT-COMPANY>
<FILED-BY>
<COMPANY-DATA>
<CONFORMED-NAME>CELGENE CORP /DE/
<CIK>0000816284
<ASSIGNED-SIC>2834
<IRS-NUMBER>222711928
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>425
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>86 MORRIS AVENUE
<CITY>SUMMIT
<STATE>NJ
<ZIP>07901
<PHONE>(908)673-9000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>86 MORRIS AVENUE
<CITY>SUMMIT
<STATE>NJ
<ZIP>07901
</MAIL-ADDRESS>
</FILED-BY>
<DOCUMENT>
<TYPE>425
<SEQUENCE>1
<FILENAME>c06801e425.htm
<DESCRIPTION>FORM 425
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 425</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt">Filed by Celgene Corporation<BR>
Pursuant to Rule&nbsp;425 of the Securities Act of 1933<BR>
and deemed filed pursuant to Rule&nbsp;14a-12<BR>
of the Securities Exchange Act of 1934<BR>
Subject Company: Abraxis BioScience, Inc.<BR>
Commission File No.: 001-33657
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The following document represents a memorandum that was distributed to employees of Abraxis
BioScience, Inc. (&#147;Abraxis&#148;) relating to the availability of Celgene Corporation 401(k) Plan to
eligible Abraxis employees upon the consummation of the acquisition of Abraxis (the &#147;Merger&#148;) by
Celgene Corporation (&#147;Celgene&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Forward-Looking Statements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">This material contains certain forward-looking statements (included herein or incorporated herein
by reference) that involve known and unknown risks, delays, uncertainties and other factors not
under Celgene&#146;s control. Celgene&#146;s actual results, performance or achievements could be materially
different from those projected by these forward-looking statements. The factors that could cause
actual results, performance or achievements to differ from the forward-looking statements include
the risk that the acquisition of Abraxis may not be consummated for reasons including that the
conditions precedent to the completion of the acquisition may not be satisfied; the possibility
that the expected benefits from the proposed Merger will not be realized, or will not be realized
within the anticipated time period; the risk that Celgene&#146;s and Abraxis&#146; businesses will not be
integrated successfully; the possibility of disruption from the Merger making it more difficult to
maintain business and operational relationships; any actions taken by either of the companies,
including but not limited to, restructuring or strategic initiatives (including capital investments
or asset acquisitions or dispositions); and other risks that are discussed in Celgene&#146;s filings
with the Securities and Exchange Commission (&#147;SEC&#148;), such as Celgene&#146;s Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and in Abraxis&#146; filings with the
SEC, such as its Annual Report on Form 10-K, Quarterly Reports on 10-Q and Current Reports on 8-K.
Given these risks and uncertainties, you are cautioned not to place undue reliance on the
forward-looking statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Participants in Solicitations</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Celgene, Abraxis and their respective directors, executive officers and other members of their
management and employees may be deemed to be participants in the solicitation of proxies from
stockholders of Abraxis in connection with the Merger. Information regarding Celgene&#146;s directors
and officers is available in Celgene&#146;s proxy statement on Schedule&nbsp;14A for its 2010 annual meeting
of stockholders and Celgene&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2009, that
were filed with the SEC on
April&nbsp;30, 2010 and February&nbsp;18, 2010, respectively. Information regarding Abraxis&#146; directors and
executive officers is available in Abraxis&#146; proxy statement on Schedule&nbsp;14A for its 2009 annual
meeting of stockholders, Abraxis&#146; Annual Report on Form 10-K for the year ended December&nbsp;31, 2009
(the &#147;2009 Form 10-K&#148;) and Amendment No. 1 to the 2009 Form 10-K, that were filed with the SEC on
October&nbsp;30, 2009, March&nbsp;12, 2010 and April&nbsp;20, 2010, respectively. Additional information regarding
the interests of such potential participants will be included in the proxy statement and the other
relevant documents filed with the SEC when they become available.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Additional Information about the Transaction and Where to Find It</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The information contained or incorporated herein by reference in this material shall not constitute
an offer of any securities for sale. The acquisition will be submitted to Abraxis&#146; stockholders for
their consideration. In connection with the acquisition, Celgene and Abraxis have filed a
registration statement on Form S-4 and a proxy statement/prospectus with the SEC on September&nbsp;14,
2010 and intend to file other relevant materials with the SEC. Investors and stockholders of
Celgene and Abraxis are urged to read the registration statement, the proxy statement/prospectus
and other relevant documents filed with the SEC when they become available, as well as any
amendments or supplements to the documents because they will contain important information about
Celgene, Abraxis and the Merger.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The registration statement, the proxy statement/prospectus and any other relevant materials (when
they become available), and any other documents filed by Celgene and Abraxis with the SEC, may be
obtained free of charge at the SEC&#146;s web site at <I>www.sec.gov</I>. In addition, investors and
stockholders may obtain free copies of the documents filed with the SEC by directing a written
request to: Celgene Corporation, 86 Morris Avenue, Summit, New Jersey, 07901, Attention: Investor
Relations, or Abraxis Inc., 11755 Wilshire Blvd., Los Angeles, CA, 90025, Attention: Investor
Relations. Investors and stockholders are urged to read the registration statement, the proxy
statement/prospectus and the other relevant materials when they become available before making any
voting or investment decision with respect to the Merger.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><IMG src="c06801c0680101.gif" alt="(CELGENE LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Date: October&nbsp;8, 2010

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">To: Abraxis Employees

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">From: Stephanie R. Werner, Associate Director Benefits and Programs &#151; The Americas

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Re: Celgene Corporation 401(k) Plan / Abraxis 401(k) Plan

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Celgene recognizes the importance of providing communication to Abraxis employees as early as
possible relative to the Celgene Corporation 401(k) Plan. With this in mind, we wanted to take this
opportunity to share some essential highlights regarding the Celgene Corporation 401(k) Plan
contingent upon finalization of the Celgene / Abraxis merger. Additionally, we have also taken the
time to reiterate some important points relative to the Abraxis 401(k)&nbsp;Plan as they may have a
bearing on the Celgene Corporation <font style="white-space: nowrap">401(k)</font> Plan. A hard copy of this letter and the accompanying
educational material have also been mailed to you from PNC our third party administrator and record
keeper for the Celgene Corporation 401(k) Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U><B><I>Celgene 401(k) Plan</I></B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Effective immediately Celgene Corporation is working with PNC to establish and expedite all
administrative procedures necessary to enable eligible Abraxis employees to participate in the
Celgene Corporation 401(k) Plan as of November&nbsp;1, 2010. To ensure a smooth implementation for your
desired elections please be aware of the following enrollment guidelines:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U><B><I>Enrollment Guidelines</I></B></U>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B><I>Enrollment Period</I></B></U> &#151; Initial enrollment into the Celgene Corporation 401(k) Plan will
be available through the PNC Retirement Directions Website from October&nbsp;8, 2010 through October&nbsp;22,
2010.</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B><I>Getting Started</I></B></U> &#151; Accessing the PNC website is as easy as visiting
<U>www.retirementdirections.com</U>, clicking on &#147;plan participant&#148; and registering by indicating
your social security number as your UserID and your password which is your date of birth (MMDD).
Access to this site is effective immediately. If you need help navigating the PNC website to enroll
you can contact PNC&#146;s customer service center by calling 1-800-374-4631.</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B><I>Helpful Tools and Resources</I></B></U> &#151; The attached Retirement Directions Enrollment Booklet
contains the following materials to help you understand the plan and facilitate enrollment:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Plan Highlights</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Educational Material</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Funds Facts Sheet</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Enrollment Guidelines</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Additional details regarding the Celgene Corporation 401(k) Plan can be found in the Summary Plan
Description available through the PNC Retirement Directions website at
<U>www.retirementdirections.com</U>. You will be provided a copy of the Summary Plan Description
following your enrollment in the Plan. If you would like a paper copy of the Summary Plan
Description before that time, contact PNC at 1-800-374-4631.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B><I>Automatic Enrollment Feature</I></B></U> &#151; Please note that the Celgene Corporation 401(k)&nbsp;Plan
contains an automatic enrollment feature. This means that unless you elect not to participate or to
contribute at another rate prior to October&nbsp;22, 2010, you will automatically be enrolled in the
plan at a deferral rate equal to 3% of your eligible compensation effective November&nbsp;1, 2010. If
you do not make an investment election, your investment direction will default to the appropriate
T. Rowe Price Retirement Fund based on your projected year of retirement. If you do not want to
participate in the Plan at this time, you will need to visit the PNC Retirement Directions website
at <U>www.retirementdirections.com</U> and indicate your contribution rate as zero by October&nbsp;22,
2010.</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B><I>Contributions</I></B></U> &#151; Your contributions to the Celgene Corporation 401(k)&nbsp;Plan are
permissible for the first time effective November&nbsp;1, 2010.</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B><I>Maximum Contributions</I></B></U> &#151; As you are making your enrollment decisions, please note:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>IRS contribution maximum(s) for 2010 (i.e. $16,500 maximum for standard contributions and $5,500
maximum for catch-up contributions &#151; combined Pre-Tax and Roth 401(k)&nbsp;contributions) apply to all
plans in which you have contributed for the calendar year. Catch up contributions are additional
contributions that are permissible for those employees who are OR who reach age 50 during the Plan
year.</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Please note that the contribution maximum is cumulative and DOES NOT start over effective
from your date of participation in the Celgene Corporation 401(k) Plan. As always, you may want to
consult with your tax advisor on such matters. <B><I>Catch Up Contributions</I></B> &#151; Please note that the PNC
Retirement Directions Website will record ONE contribution election ONLY. As such, you will need to
take into consideration your TOTAL desired contribution election (regular $16,500 and catch up
$5,500) when indicating your contribution percentage.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U><B><I>Plan Provision Highlights</I></B></U>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B><I>Vesting &#151; Your prior service with Abraxis will count towards vesting</I></B></U>; Employer
contributions and earnings on those contributions are 20% vested after 1&nbsp;year; 40% vested after 2
years; 60% vested after 3&nbsp;years; 80% vested after 4&nbsp;years and 100% vested after 5&nbsp;years. You are
always 100% vested in both your salary deferral contributions and the earnings on those
contributions.</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B><I>Roth 401(k)&nbsp;Feature</I></B></U> &#151; This feature of the Plan allows you to set aside money from
your paycheck after it has been taxed, but the money can then grow on a tax-deferred basis and
contributions and earnings can eventually be withdrawn tax free.</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B><I>Company Match / Discretionary Contribution</I></B></U> &#151; This feature provides for a discretionary
match on your Pre-Tax and or Roth Contributions up to the first 6% of eligible compensation. This
discretionary match is generally made on an annual basis on behalf of all eligible employees that
are actively employed through the end of the year. The Company Match is made in the form of Celgene
stock and is typically deposited into your Celgene Corporation 401(k)&nbsp;Account by the end of March.
The amount of the match and the decision to make a contribution are evaluated on a year-to year
basis based on profitability. Currently Celgene Corporation does not have a per pay period match in
place.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Please note that while this memo describes highlights of the Celgene Corporation 401(k) Plan, it
does not include every detail or limitation. If there is a disagreement between this memo and the
official Plan documents, the Plan documents will control.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U><B><I>Abraxis 401(k) Plan</I></B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U><B><I>Vesting, Contributions, Loan Repayments</I></B></U></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As you were previously notified by Abraxis, effective October&nbsp;14, 2010, the Abraxis <font style="white-space: nowrap">401(k)</font> Plan
will be terminated. You will retain the ability to make investment direction changes in
accordance with plan rules. No employee contributions, company contributions, and new loans will be
permitted in the Abraxis 401(k)&nbsp;Plan after October&nbsp;14, 2010. If you currently have an outstanding
loan balance <B><I>your loan repayments will continue through payroll deduction and will be
remitted to the current record keeper, T. Rowe Price, consistent with current procedures. </I></B>If you
take a final distribution from the Plan, you can either repay your outstanding loan balance in
full, or else your distribution will be reduced by the amount of the outstanding loan balance and
the outstanding loan balance will generally become taxable. In either situation ongoing periodic
loan repayments will terminate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U><B><I>Distributions</I></B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Hardship withdrawals and distributions from the Abraxis Plan will continue to be permitted.
Rollovers into the Celgene Corporation 401(k) Plan will not be permitted until Celgene receives the
IRS approval letter for the Plan termination. Once IRS approval is obtained, if you elect a
rollover to the Celgene Corporation 401(k)&nbsp;Plan and have an outstanding loan balance, you will
also be able to rollover your loan balance if you so choose. Additional communication will follow
once IRS approval is received.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U><B><I>General Benefits Information</I></B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Other benefits that were previously available to you as an Abraxis employee will remain in place
until further notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We look forward to working with you as we manage the transitions for both of the above-mentioned
Plans.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>c06801c0680101.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c06801c0680101.gif
M1TE&.#EA<`!B`.8``.;HZOW]^5%-<B<F9/O\]/[^_M/;Y(V*D=SDZ=G6V1@5
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MD"\Q<3`M3RPK:[2POF1IHJNOS3P^?K"OL9N=G\W+QO#P\?___R'Y!```````
M+`````!P`&(```?_@'^"@X2%AH>(B6%R,VPI,!L%B9.4E9:7F)F$&P$!(R,^
M&1F:I*6FIXDC*5]&5@`!HZBRL[1_!9)_806Z9@E()"XT&V&UQ<:E8<,C=P(W
M.AHQ%S#'U-63PV8E=F(Z`U!/#]/6X^0]"3PR=G0#53(N$G+D\L4%&3`P7$EB
M8G95`P-C:H"I<$N2J'D(-64(8,9("!UCQ'BC($/'MP>B;AU,R+%2F!%(;@SH
M-H`!%`HFH;R3`ZM>QY>&=@GB4,))11TZ*-R`PL`%%)4D*@2`44"+%I@OPV3H
MH65&F"](=#CYQZ!*.PT:7&@8H](`C!%LM+A$FA!7O38"[-AAQT`'@Y(4_RA@
M_>EB1X`-L6*1G9>A(!,!4]]:?<L`*U:Y4#2`.<*FKQ:]>\G!RB`DK1V(A%$:
M=N&"0F(-#!"P&7HT,M\-3'A,K?+$+0,&,N*^=D)B08P836Q$@$3,]+P`":RH
M&Z`!2FP7588T.2'B`8(+1")$.,*AP[``?TK[MO;W+5P*='"<:/"!B8,B2TJ@
M$&!E010>+"[@[;N=UBU;L&!P0/>/P@`P$C1@0!M%L!#%#SC)H*`,&LCPV@-R
M9)""=O6=HM%",T2`A'\,/(%#'@@D4`0/0?#T&E=NR3"&!E5`$8<7*W0``QL5
MRI)1`3`0$-(-=C3Q`1%WH.`$2G)ID--G<?V4F/]``'0P`X4UDE*/*",LH0`=
M%GR0P!)#./C::PZ"MJ(&B&%50PT,T$!`&1M$>4H8;'"R1Q`QE+=$"#+<X&5A
M6'V9V$EQ%4=!#7&P0,`,/KAI2@8;;`!`"1,@@(8`"LKV5FQR>=9@<8:9>>8/
M+/6FJ"8PS""A&1@$<0-*)C7X&JLE_<1G<3(8-T:M+AB@!7:C*I2"'%RD=0,6
MH+UV6%RL=L9A%<]\:1(%<5AP:*^37)@"G`%\`4*)7+EP@Q0*2&''#PO@88$%
M$J1K`0X+(/BE2+3>H,01N%!;[4(`.)0G!4\,L0`(.=#PP10(,/$`!G?00,,#
M'PAQ1`1,M.%%#'K8(5+_%1HH\$";]A[25ST!M(&"#&+\@(,%(A@```<`M#!!
M"7,(0()-))``AA4E7-&!*&$<D<`$"]A!P1@O0M;Q($R%$4$72IALPP<5K.##
M%PYD$4*)-3BHPQ`2["`@`GX<(=8MCW7@1PMS#`G&"D<;`L0(4_`0P@D(M+%$
MDU_<<;5(*U+P0Q,-7"!'6`4=HA1##X2@``)M%U*&&U1@`(`)`@R1!P=W-LML
M%72\@<`*G(0AND8>]X!C!GY,<$'CA(1AQA034!K%`R\(X!;&-;A`@@4/'!&`
MZ!]+(I,A+8F^`1N)4BL\R+D0401@`X#P\P]R5875$SM<T$%8NA1N2[V$9`#\
M_^]A!+#\J+CPE@`$0;SF!0!(;.."EWY#B!?XEBPD>@`S0'*4+HKJBRX(@+D@
M2&$,`S@!``0`!8G`Q@4*`(-HAD(43>QB?QF8`A=\(!911>DQ!6@##Q)S@S%L
M(6X:N(&QH""%(2#`!_=@@P<OH10S>&`")DB"#"+`AONXJ0`;(``70G"#,\5!
M`A_@@6PTHP$]/&`&<F@4\K0@.BWT8`,S\L$,>%6(`@1@"@((PDAN4(''0*D^
M$O*`$H:6,0$P`0E2>!9H:J"!'1PAB"/`RP828((2@,"/!UC"$0A@-$&4;P1,
M@``#QB"%"^R"1CZLSPP\`(4!["0.-T!`"110&`9`R_\%4K``$#)PJ%T)`04U
ML.0_N*$`,HC/<.7;P`L4H`$I$`0&8G%3"V0`$#+%X0T)J,,85I6[N)#@`F5@
M20"TX(`DC$$/%K#!"5`PAI[L0"F'N*`69LD`!3@R`S0RRDN\9TA(M"`$_UB1
M"^A`A"2HL$@4<$$<U``Z*@;@"DJ001->R(8.C."<"E"!#^30@3#`H!/6V8`/
M4K"!/G"2`A7`XF@,RH;1\$R&9?#!0LTP'3FHXG@I2$$`KE71#G3@$7"*$U&.
M\`4`?&$$!!#I'T:1#`Y$022+E*<-9BD&3V8M+E6X0",R,#4=_L``,EI("@BP
M216`DPTP0-4)IJH&`#3"`0K_H$`CV3"#(`*@#4:8``:84#`F&`P(SBO!N4Y@
M`!\@E`D?R*,0,+"$)33@"*,C@!D<H)XH1.$$R$R!1@I``#X$02(8H\@%E-C3
M)<8!!RM@:`#88(*L2J`#!)A1HP+@`"4\("P$6%\=O*,#-[+!H5J]P$*_<(`P
M&D<'/QA"$D(0`AQ\8&0XM0,8RL,%%H3`%6I(@@XL)H83K$"&$3A`'710D<ND
M`0#B6P@,RA""?C``"Q10P`*$P,D!(,N3+CA!``C@5C,HP1ED("_Y.C!0!+`W
M`RTXK![8A06`\,`/LZSE!0C0!AW2`0^^Y>48QB"5+3!P`4TH`3K'@(,WX&D,
M)*`4_QBB0`(=5*$&'R``$.8`A1^`X`T.=HL$5@"#'AC4`6H9@(HRM@6']D<K
M8_#/!WR`Q2]F]:APZN)C-B"$$$AA`08X@A],4`-&3N`,"I"!%.J63S#T;@0`
M@("*:O"`!?H-`4<H0P)T<`,-3&`/XJJ!`%IP`0XX`)TNL,$(^.!),FPQ!1@P
MSAIH4!0<(:$M8!I#,$H@!7]0I`J>_(%0#!J`/2B@!@NH`)R6-XJB]``"-W@"
M&5@"`R'HD`(QX$*278``"&1E!T"0T0P<$`0=Q"$'E!R##0C0J#)0J@8XX((4
M=(`%$6Q@J5]`03=M`,8F2J,'!&!"'1S4!%MDX`M*&,F7-/_P!`/P@#.%@0*@
M%1"%(V1`"P<U@10T@(,*5'1YM^A$!.IP@R$8(`)$($)W&&`%#"C@!B[X@!)Z
MTH`XA<%LE#HB!"A0!3*T]`(+E`&B'>`"+!SU4&'P@ZX5X(4N),8*3````N9:
MAR#(``=32H"T6P,:"I!@"B&(9R=AHX`W%)2*.H)WMX$W)5UTP@,4T`$=TE""
M-*!`-62R@J:ST@">U(`,>3R>&000SR@$`0M0``,/V).6PBS@!5*0`0D^,)0`
M<``%V=U!"?C]A!`,80AA1#H4).!%SO*;N1TG`1-"[@(^#8T">:BS%WD`[RBL
M8`9>5(IC=A42#="A"4TX%PO.90'_&CB4Y\-F^!UG,(,>9Q</);*#!*:Z@QWD
M(0<3:,,L_6:`F2H-ZW5!I0;PX`"%T:`!#VA``_QP.`S<I%A75H(4_%.<G\#=
M+%HXP+87<`1<0E4I1=F5/K1;@1%$40N89:]#5_4`)?!$!RTX@@]&<(`X:/<,
MV];!!XQ"Q<VR8990(($!O*@?75.`#%:H@0)L@%FE'`\2@BU?$?S#W*KHC@E)
MD$V#!*X!$=SG%D:P*C_P`3LS.AJA!1O@3A0P$)-149S04%E%`9(R*'XS!TN`
M`D&@`0O`!%<P>U7P6;MP/)P0`%#78>,G/A&`=1J@`BB0,3:P`AA4/G<1!KN"
M52-Q$@-0_P-K8`!),'N>]"<40`.=H!0$T`)2H!(J0$CW4!#VD`+N)!#[14$*
M=1<.Y4EE-@$AYTDCL0!O@%0)$($[,!IW46.RE&0_@`!%D0$1L&\NH`(L(`6P
M)@>/(4"=,`J/D0!Q,!*N$0?-UH-5T65:$0Q#&`8$``!Q(`84@`.^4S[!<U!)
ML$@#\``PJ`LY4@9`X%!*5@$BI0W,00,`L`($0`"ZD$\NT`1N%4,SL%0>(`4W
MH`<(,`H]D(+9Y07:EA5M-3IW@58TF`%,D$H0`6A9\0`0X($[P1,4(`)?,`Q>
ME`%T9TD3,'T;L#.B0`![0`$]Q0#=YA0R.`51X`&<%`<7$`!H$/\'"[!?>,>(
M][!OUV4`G)`!+-$"2+"*.N"*C:8AV:4"?:`$5>`"5B`4I!0`$>!':>@'<.`/
M6U$8"C`!WL@B)D%'<(<&3%`/!G4%-7`#-[`&>3`",-`]87`'-8`'`F!_+,`8
MC3(%2L`"4*<`G/8`.O$$-@`V7P!P```$E08%2+<`<74H+>`$)P!F=>"*D[&&
M,J``$@`$PS@`+C`'4S`:418$G2<(&7``%V,]"A`#5Z``_T`F+H`F><`'?#`4
M10$#)F"-K`$"&/``-#`!**`#T2`$/[!(I04"1H`$0;``DI)*"O`!?0`%*L0L
M,T,;_5("!K`$-R`&&D`"<P`"MH,""*#_>SI``B)`!#("`#R@9R@P,,T@`VL0
M`BR``B1@!R?0)HV6`"137R6A`'K``:I2&'$18SU)`GY@/C@"!"A@D5B`!;3A
M!#K@(7[`"1@P!#'7%KP$!@;P`GA")@M@-T[P%C8Y!K>)!3H@9@GP!C;AG+<"
M9!Y0!6*`="0``BL0`"8@1AJ`!21`-SR@`]S@%G1P`D0@FK9``"'9#6Y!)A\`
M1ZR)%7$0`WT0!P^@A!("`$N@FUC@#QZB!D303YG%!"#0+C\`!EN``(5E!5&`
M`U:``Y+8!@;B'@O0+A`Q!@I@`D?@`"B@!^1R`*]0!%X``G\T!Q,@!QVIHBK*
M`BV0`F9P!W/@_U>\`P2W]C$+T0)8T`_/H`'1T@=1YTER$0<",`5QT`1``%7C
ME0P`0`->X`4J`#4^($,ST@D$P%(7$`$R0EXK<`1`$*9?P`=$(`=F<`1JRE)<
M``=*%@,R4@9$\`4\M%2AN`$916/\<U`=$``R(IN'L@)2@VTP<"->!!*I%"8L
M<@%P$$>=Y`)/@`#ZV)^-`$"W4%&$$TF8$``>Z5Z=T!(!4`9=(`5')".[&#SX
M,PMYEP#QB3$>N@5H8)$KX@X?"`&/!0`IX`,%L:N\.@BIB@@@H0`G$$4&V`G:
M-@8-L`%.P:N::A^BTP%JQ`Y5@%TD@`!T9Q6)X0(@P`5Q0`$[D%F^NO^KW_.K
ME&`&&S($+?`%TB=T":`$ZV<&_",*&TFNJGH+A.AN)<$`-Q`'6[!+BV0F8/`%
M=>!Q"(!W1M$#J*H)!A5+1A`'5>`$*``":H`!&%`"0\``$F!MO\,SS5H-85`&
M)B`1V^"A!J![^NI=$A@%AZ8'1``+1G$^EN!#!?`(9C"G=Z8G`X`%O/0$"_``
M;D467E0&19!.,E`%<V"M%OD:"M``+5!"8Q`%$7`__W<)4X(C!!`!/*`"&V`&
M;6`",`H"._`C#$4C2,$H*0`$1?`#U32M;]`&->`/-Z``:1`!5B`%Y,8"32(^
M>D>U0U@`0L`#K712!*`%<3*&([617#1.P-/_`0X@``.P!@SP`UWK'UT6J1A0
M!;>"!752@,,P-JFZJZ+`":E12=HCM<Q*3N.$"Z)P!#R0LRZ``Q?0#/JZ?D#`
M9]T@`TZ0`T=P+9Y+KX1+2FA!!U(0!8M&K_5!:!G`!P,@!J4X!>V#78GV!>(R
M+'1D!1]P1]WSN061+<J%!6NPM/9JO'M!-@)$#*&U`%+@`B*P!W50!8/2``3P
M`'&`!3_8%@(P`0#0&#!K"\DP!4B@MNBIKZO308W3`RD0`3DP!%6``1,08Q30
M!$0@!$M0`Q*1LV(PK22``F\P`7?0`BUP!Q.0`R`@-W\Y7#F!`_'`.H(@(PP%
M`#'C`&]`$>!P`%\`_VDEI`'YJF(WX00VD:^X^P]6`1$*L`-G=#2<<`]?X0$>
M0`3H4`--\`)6\`5*-`:8^Q,K\EI6W*$$]@_,A2OYJ\*",`,$@+`+$:HI```A
MMP9K9P%3D`76N")`O!46YBPV82+^H!)#<&]@C`@2$FP"D)](%@-,,`$64Q*#
M83TKLFQYIB`!-11[G$T9H`IH(04?,(RSTP+-(!(4T2>L`B:>I"+-@@"_\\@Q
MX:>WUJY1,`4DP`!@D`<)4`+KH"D=YRQ&&AM8(!!Y5$B/?"%W\05P@`%J`!H#
M,`<&@`!8R(I&4A@#5DUD,GM$`P(L00"DS,>=P`8`<`!$@`1M=P,DP`)M`/\`
M&,`">B`&<<0J_&8<:,(`#2`C/3#-B)`,%64&J)$$)8$5B)D#9M4";U`"5A`"
M3W`33P"Y%M"R!^7.V42#<1)$=W`Q&&,D"R`!(O`!%W`!<(4!IW=Z&+!?]M`!
M!GTO7F0"\#(FAZ$!0Q`#*FH$'LP%$V``IF(+'3T)`E0`9D!$)1$FK_$9B>$?
M<N$"%A`)&_'2A_`[(-.NN<6:;:=BK^&JI[8S]2"^[EP0A`NMZ%0%_;"V@U'/
MH%$%".#38P'4B+`+!3`":E!?%L9ETF9A@(8K.``$+N?4+WU!'S$!/+*\]"L8
M+0(%>D8&,E(4+NW57]T],%"[ZF`5(B&MQ9$[!A"4108Q0W[MJ]W3"69@`A96
MP>Q0*RXR!$<P`DQM/HU-"67G!TO`#Q7<#O;7!,J42YWMV9TP`WY@!!?,#OU1
M&'GP>Y"4VC`]64$4!GM0$4"\(C]P`3UP#]A1J+:="(-E#PD0`E3M#6,`#Y[[
M/<7MV;:`&DA`,M)&`XP=W9Y=$`=\S%'PBMJ=";LZ63/07VH@!VX=WAT="``[
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
